SCHEMBL2773469

SCHEMBL2773469

CCOC(=O)c1ncc2onc(-c3ccc(C#N)cc3)c2c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
ELANE P08246 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
HPGD P15428 2/20 0.39
EGLN1 Q9GZT9 2/20 0.38
POLB P06746 1/20 0.38
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GABRA5 P31644 1/20 0.36
SLC34A1 Q06495 1/20 0.36
FLT1 P17948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2775257 0.88 RXFP1 (0.47) ELANERXFP1HPGDEGLN1POLB
SCHEMBL2777192 0.86 SLC26A6 (0.46) TP53LMNAMAPTHPGDKDM4E
SCHEMBL2774483 0.86 TARBP2 (0.47) LMNAMAPTHPGDPOLBKDM4E
SCHEMBL2777901 0.86 TARBP2 (0.47) LMNAMAPTHPGDPOLBKDM4E
SCHEMBL2776728 0.86 ALDH1A1 (0.46) LMNAMAPTHPGDPOLBKDM4E
SCHEMBL2776812 0.85 TARBP2 (0.48) MAPTPOLBALDH1A1GAAGABRA5
SCHEMBL2776724 0.84 MLYCD (0.41) TP53LMNAMAPTHPGDALDH1A1
SCHEMBL2775759 0.83 MLYCD (0.45) LMNAMAPTPOLBKDM4EGAA
SCHEMBL2775944 0.83 PTGS2 (0.43) TP53MAPTALDH1A1MAPK1NPSR1
SCHEMBL2774763 0.82 CACNA2D1 (0.41) TP53ELANEPOLBSLC34A1HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 TP53 1685/4885LMNA 4078/4885MAPT 3874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.